- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02660944
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
El Cajon, California, Forenede Stater, 92020
- Triwest Research Associates
-
La Jolla, California, Forenede Stater, 92093
- University of California San Diego
-
Los Alamitos, California, Forenede Stater, 90720
- Valerius Research Center
-
Los Angeles, California, Forenede Stater, 90048
- Wallace Rheumatic Study Center
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33765
- Clinical Research of West Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33309
- Center for Rheumatology, Immunology and Arthritis
-
Naples, Florida, Forenede Stater, 34102
- Alper Research
-
-
New York
-
Great Neck, New York, Forenede Stater, 11042
- Northwell Health/ Division of Rheumatology
-
Manhasset, New York, Forenede Stater, 11030
- Feinstein Institute for Medical Research
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28210
- DJL Clinical Research
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- Temple University
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- Metroplex Clinical Research Center
-
Sugar Land, Texas, Forenede Stater, 77479
- Accurate Clinical Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- CLASI score greater than or equal to 10 at Baseline
- Positive for one or more RNA autoantibodies
Exclusion Criteria:
- severe, active central nervous system (CNS) involvement at Screening;
- severe renal involvement at Screening (urine protein/creatinine ratio of >200 mg/mmol, or an estimated creatinine clearance of <30 mL/min);
- use of cyclophosphamide within 3 months of the Baseline visit;
- use of rituximab within 6 months of the Baseline visit;
- use of belimumab within 3 months of the Baseline visit;
- use of background medications within 1 month of Baseline in excess of: i. mycophenolate mofetil > 3 g/day; ii. azathioprine > 200 mg/day; iii. methotrexate > 25 mg/day; iv. hydroxychloroquine > 400 mg/day; v. prednisone (or equivalent) > 15 mg/day;
- use of an intravenous steroid "pulse" within 2 months of Baseline;
- use of an intramuscular steroid injection within 1 month of Baseline;
- change in SLE medications within 1 month of Baseline;
- the presence of a clinically significant infection in the judgement of the Investigator within seven days prior to the receipt of the first dose of study drug;
- positive viral load test for hepatitis B, C, or HIV at Screening;
- participation in another clinical trial with receipt of an investigational product within 3 months or 5 half- lives, of last administration (whichever is longer) from Baseline;
- positive pregnancy test at Screening or at Baseline;
- female subjects currently breast feeding at Baseline;
- inability or unwillingness to comply with protocol-specified procedures which, in the opinion of the Investigator, would make the subject unsuitable for study participation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: Placebo
Saltvand placebo
|
Saltvand placebo
|
Eksperimentel: RSLV-132
10 mg/kg RSLV-132
|
RNase-Fc fusion protein
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo.
Tidsramme: Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169
|
Mean change from baseline (from baseline to Day 85; or baseline to Day 169) in CLASI activity scores (Last Observation Carried Forward [LOCF] post censoring values). The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations. |
Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants Achieving a 50% Improvement in CLASI Activity Score
Tidsramme: Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169
|
Percentage of participants achieving a 50% improvement in CLASI activity score at Day 85 and Day 169 (LOCF post censoring due to use of exclusionary medications)
|
Baseline and Days 29, 57, 85, 99, 113, 127, 141, 155, 169
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 132-03
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Systemisk lupus erythematosus
-
BiogenTilmelding efter invitationSubakut kutan lupus erythematosus | Kronisk kutan lupus erythematosusFrankrig, Spanien, Forenede Stater, Sverige
-
BiogenRekrutteringSubakut kutan lupus erythematosus | Kronisk kutan lupus erythematosusForenede Stater, Italien, Korea, Republikken, Taiwan, Argentina, Chile, Spanien, Canada, Serbien, Frankrig, Tyskland, Japan, Brasilien, Det Forenede Kongerige, Puerto Rico, Bulgarien, Portugal, Schweiz, Filippinerne, Saudi Arabien og mere
-
Bristol-Myers SquibbAktiv, ikke rekrutterendeLupus Erythematosus, Discoid | Lupus erythematosus, subakut kutanMexico, Argentina, Australien, Forenede Stater, Frankrig, Tyskland, Polen, Taiwan
-
SanofiAfsluttetKutan Lupus Erythematosus-Systemisk Lupus ErythematosusJapan
-
AmgenAfsluttet
-
Florida Academic Dermatology CentersUkendtDiscoid Lupus Erythematosus (DLE)Forenede Stater
-
University of RochesterIncyte CorporationAfsluttetDiscoid Lupus ErythematosusForenede Stater
-
Massachusetts General HospitalNovartisTrukket tilbageDiscoid Lupus ErythematosusForenede Stater
-
Gilead SciencesRekrutteringKutan lupus erythematosus (CLE)Forenede Stater, Spanien, Tjekkiet, Tyskland
-
University of PennsylvaniaCelgene CorporationAfsluttetEvaluering af lenalidomid (REVLIMID®) til behandling af personer med kutan lupus erythematosus (CLE)Kutan lupus erythematosus (CLE)Forenede Stater
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
West Penn Allegheny Health SystemAfsluttetAstma | Allergisk rhinitisForenede Stater